Diagnosis Value Of CA19-9 And CA125 In Bile To Biliary Tract Carcinoma

The biliary tract carcinoma is one of the rare clinical biliary tract system cancers, including cholangiocarcinoma and gallbladder carcinoma. No obvious clinical symptoms were found in the early. So the majority of patients were diagnosised in the late stage. The treatment effect of the biliary tract carcinoma is not ideal, and the prognosis is poor. So how to increase the rate of early diagnosis of the biliary tract carcinoma, is the key to improve the diagnosis and treatment. The relationship between cancer and associated genes and their protein products is one of the hot topics nowadays. And the monitoring of cancer related protein has certain significance to the diagnosis and treatment and prognosis of the cancer patients.In recent years, the tumor makers, carbohydrate antigen19-9(CA19-9) and cancer antigen 125(CA125) have been widely used for malignant tumor clinical serological detection work, and the value in clinical application has been recognized. The CA19-9 is a mucin type carbohydrate protein tumor marker. And it's recognized by murine monoclonal antibody 116NS19-9 and be named. CA19-9 serum detection significantly increased in pancreatic cancer, carcinoma of gallbladder, bile duct cancer, gastric cancer, cholecystitis, cholelithiasis disease. CA125 is a high molecular weight glycoprotein. And it could be recognized by monoclonal antibody OC125, which obtained by human ovarian serous cystadenocarcinoma cell immune to mice. CA125 detection in serum increased significantly in ovarian cancer, breast cancer, pancreatic cancer, bile duct cancer, gastric cancer, cholangitis, hepatitis disease.Clinical data show that the serological detection of CA19-9 and CA125 is positive in patients with the biliary tract tumor. The sensitivity is about 60% and specificity is about 40%. Besides, the research report about the expression level and diagnosis value of CA19-9 and CA125 in bile is few. Through the statistical analysis of the detection CA19-9 and CA125 in bile and serum of patients with biliary tract disease, we can explore the clinical diagnosis value of the CA19-9 and CA125 in bile. ObjectiveTo improve the clinical diagnosis value of carbohydrate antigen 19-9(CA19-9) and cancer antigen 125(CA125) in bile to biliary tract carcinoma. Methods95 patients were selected which were divided into the biliary tract carcinoma group and the biliary benign disease group according to the results of pathology. Serum spesimens was taken before operation and bile spesimens was taken during operation. Tumor markers' levels of CAl9-9 and CA125 in serum and bile were detected. The diagnosis vavle was acquired from the statistical analysis of the tumor maker levels. ResultsThe levels of CA19-9 and CA125 in serum and bile of biliary tract carcinoma were significantly higher than them of biliary benign disease(P all <0.05). The levels of CA19-9 and CA125 in bile of biliary tract carcinoma were significantly higher than them in serum(P all <0.05).The sensibilities of CA19-9?CA125 and combined detection in bile were 90.48%,83.33% and 92.86%. And the specificities in bile were 43.40%,64.15% and 72.63%. ConclusionThe diagnosis value of CA19-9 and CA125 in bile to biliary tract carcinoma is higher than that in serum. And combined detection of tumer makers in bile can improve clinical diagnosis of biliary tract carcinoma.The detemination of CA19-9,CA125 and combined them can be used a new method to improve the diagnosis of biliary tract carcinoma.